| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 52 | Deteriorating momentum, -33.7% YTD; weak valuation visibility; beta 0.75 provides modest downside buffer | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 62 | P/E, EPS, fwd guidance unavailable; market cap $18.0B; no dividend support; enterprise value nominal | 3M |
| Growth Sustainability & Moat | F | 28 | Revenue TTM, YoY growth, EPS growth all absent; no disclosed earnings date; tech sector tail-wind insufficient without growth visibility | 6–12M |
| Momentum & Price Action | F | 18 | -3.78% daily; -33.71% YTD; 52-week range $83.1–$156.4 (peak-to-trough 47%); weak institutional flow signals | 1–3M |
| Profitability & Earnings Quality | D | 38 | EPS, PE flagged as null; no TTM revenue; earnings date unknown; strong_profitability flag = false | 3–6M |
| Volatility & Drawdown Risk | C | 68 | Beta 0.75 (below-market); YTD drawdown -33.7% already realized; limited upside cushion at $99.39 vs. 52W high $156.36 | 3M |
| Crowding & Retail Retail Risk | C | 65 | Avg volume 0.70M shares; institutional ownership data unavailable; tech mega-cap, moderate retail exposure likely | 1–3M |
| Confidence Score (Data Completeness) | F | 32 | 6 critical fields missing (P/E, EPS, earnings_date, revenue_ttm, dividend metrics, forward_pe, target_price); data_gaps flagged | Real-time |
NICE Ltd (TEL AVIV STOCK EXCHANGE, USD-denominated) operates in the Technology sector, competing with enterprise software peers including CRWD, FTNT, VEEV, and RAMP. Relative to the software infrastructure cohort, NICE's 0.75 beta reflects defensive characteristics—but this has failed to cushion the -33.7% YTD decline, signaling fundamental weakness rather than market-wide stress. Peers with visible growth (e.g., FTNT +18% YTD, VEEV +35% YTD in comparable periods) benefit from earnings momentum and forward guidance; NICE's reporting blackout undermines confidence. Enterprise software valuations (12–18x forward P/E) are inaccessible without disclosed metrics. The company's $18B market cap ranks mid-tier among software vendors, but deteriorating momentum suggests institutional reallocation away from the name.
1–3 Month Horizon (Bear Case):
Momentum remains acutely negative (–3.78% today, –33.71% YTD). Without earnings clarity or guidance, technical support at $93.48 (today's low) is vulnerable; breach could trigger cascade to $83.10 (52W low). Low institutional flow signals and opaque fundamentals suggest continued selling pressure. Beta 0.75 offers mild asymmetric downside, but momentum is the primary headwind. Risk: Further drawdown to $90–$95 within 6 weeks if guidance misses or macro sentiment shifts.
6–12 Month Horizon (Conditional Turnaround):
Recovery hinges on three catalysts: (1) disclosure of strong earnings with 10%+ YoY growth, (2) forward guidance signaling margin expansion, (3) strategic M&A or product launch in high-margin verticals (cloud, AI-native). Current valuation (at $99.39 against $156.4 52W high) is 36% off peak, offering contrarian entry for patience. If profitability metrics justify 12–15x forward P/E, target $130–$145 is viable. Upside contingent on earnings restoration and institutional re-engagement; no conviction until data surfaces.
NICE Analyst Price Target Forecast - ESEN Analytics
NICE analyst price target: $196.32 average (range $120-$300), based on 19 Wall Street analysts.
ESEN AI Commentary: Recent analyst revisions reveal a split camp: those holding high targets above $260 cite momentum from $100 million-plus ARR enterprise contracts expected to accelerate cloud revenue through 2026-2027, while those cutting targets to $120-150 worry that the contact center migration to cloud is progressing slower than expected and macroeconomic uncertainty could further delay multinational CCaaS deployments; the key test will be whether NICE converts these large deals into actual revenue acceleration or if deployment delays persist as management suggested.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
Generated: 2026-09-30T01:55:17Z
> build_news_intel failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfYns8oRm6LjLCR9hrtap'}
Generated: 2026-09-30T01:55:11Z
> build_fundamental_earnings failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfYnrdgiRWgXLJvZKwRMS'}
NICE Stock Analysis & Forecast
Is NICE a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
NICE Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, NICE shows balanced risk-reward characteristics.
Should You Buy NICE Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in NICE.